Back to search
Monoclonal Gammopathy of Undetermined Significance
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Monoclonal Gammopathy of Undetermined Significance trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Monoclonal Gammopathy of Undetermined Significance trials you may qualify forBlood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the can…
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, i…
This prospective, multicenter, observational study aims to identify molecular and immunological markers associated with disease progression in patients with mon…
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering…
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifa…
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MG…
The objective of this investigator-initiated phase II single-arm open-label clinical trial is to investigate neurological response rate, safety and tolerability…
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of un…
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). T…